课题基金 / 基金详情

项目摘要

项目成果

Michael S Wolfe的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The last step in the production of the amyloid--3 peptide (A?), the primary component of the characteristic cerebral plaques of Alzheimer's disease (AD), is intramembranous proteolysis of the A-3 precursor protein (APR) by ?-secretase. This protease long eluded identification because of its complexity. Nevertheless, the past few years have seen considerable progress toward understanding the biochemistry of ?-secretase, and small molecule inhibitors have been indispensable tools to this end. Specifically, we and others have found that (1) ?-secretase is inhibited by substrate-based analogues containing aspartyl protease transition-state mimics; (2) the multi-pass Presenilins (PS), mutated in familial AD, contain two conserved transmembrane aspartates essential for catalysis; (3) PS is the target of transition-state analogue inhibitors of ?-secretase; (4) affinity purification of ?-secretase activity with an immobilized inhibitor isolates not only PS, but also three other components essential for activity: Nicastrin (NCT), Aph- 1, and Pen-2; (5) the protease apparently possesses an initial docking site for substrate on the outer part of an essential signaling pathway in cell differentiation and embryogenesis. ?-Secretase is a founding member of an emerging family of intramembrane proteases that apparently have their active sites embedded in the lipid bilayer. Despite the remarkable progress, much remains unknown about this unusual and important protease. Toward advancing the mechanistic understanding of ?-secretase and exploring its potential as a therapeutic target, we propose new substrates and inhibitors as molecular probes. These new molecular probes are designed to address three specific aims: (1) What is the nature of the ?- secretase active site? Of the substrate docking site? (2) How does ?-secretase recognize and handle its substrates? (3) How can ?-secretase be allosterically modulated to block proteolysis of APP but not Notch? Lay Summary: The goal of this project is to understand ?-secretase, a complex enzyme critical to the cause of Alzheimer's disease. Small organic molecules will be used as probes to characterize this enzyme, elucidate how it works, and explore its potential as a therapeutic target.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
Distinct pharmacological effects of inhibitors of signal peptide peptidase and gamma-secretase.
信号肽肽酶和γ-分泌酶抑制剂的独特药理作用。
DOI: 10.1074/jbc.m805670200
发表时间: 2008
期刊: The Journal of biological chemistry
影响因子: --
作者: [Sato,Toru, Ananda,Kuppanna, Cheng,CathyI, Suh,EricJ, Narayanan,Saravanakumar, Wolfe,MichaelS]
通讯作者: Wolfe,MichaelS
DOI: 10.2174/156720510791050920
发表时间: 2010-05
期刊: Current Alzheimer research
影响因子: 2.1
作者: [Augelli-Szafran CE, Wei HX, Lu D, Zhang J, Gu Y, Yang T, Osenkowski P, Ye W, Wolfe MS]
通讯作者: Wolfe MS
Structure and Function of Gamma-Secretase in Familial Alzheimer's Disease
  • 批准号:
    10388359
  • 项目类别:
  • 资助金额:
    $58.21万
  • 财政年份:
    2020
  • 负责人:
    Michael S Wolfe
  • 依托单位:
Structure and Function of Gamma-Secretase in Familial Alzheimer's Disease
  • 批准号:
    10605227
  • 项目类别:
  • 资助金额:
    $58.21万
  • 财政年份:
    2020
  • 负责人:
    Michael S Wolfe
  • 依托单位:
Mechanisms of Gamma-Secretase
  • 批准号:
    10004095
  • 项目类别:
  • 资助金额:
    $29.16万
  • 财政年份:
    2017
  • 负责人:
    Michael S Wolfe
  • 依托单位:
Mechanisms of Gamma-Secretase
  • 批准号:
    9566224
  • 项目类别:
  • 资助金额:
    $29.16万
  • 财政年份:
    2017
  • 负责人:
    Michael S Wolfe
  • 依托单位:
海外基金